

Q4 2017 Financial Results SALES WORLDWIDE

+7.7%
ON COMPARABLE
OPERATIONAL BASIS*

+42.3%
ON REPORTABLE BASIS

Strong Performance in CORE BUSINESS SEGMENTS¹ SALES ON COMPARABLE OPERATIONAL BASIS

DIAGNOSTICS



+6.7%

MEDICAL DEVICES



+9.6%

NUTRITION



+2.0%

ESTABLISHED PHARMACEUTICALS



+14.0%

FULL-YEAR 2018 GUIDANCE

\$2.80 TO \$2.90 ADJUSTED EPS, MIDPOINT REFLECTS 14% GROWTH.²

Life-Changing HEALTH TECHNOLOGY MORE THAN 20 NEW PRODUCTS LAUNCHED IN 2017



FREESTYLE[®] LIBRE

Launched in the U.S.

This revolutionary glucose monitoring system eliminates routine fingersticks³ for people with diabetes and is now approved for coverage by the U.S. Center for Medicare & Medicaid Services.⁴



CONFIRM RX[™] INSERTABLE CARDIAC MONITOR (ICM)

Launched in U.S. & Europe

The first and only smartphone compatible ICM helps physicians remotely diagnose and treat difficult to detect irregular heartbeats.



ALINITY[™]

FDA Clearance for CI-Series

The game-changing family of diagnostics systems stand to change the way labs work to deliver results that drive better patient outcomes.



XIENCE SIERRA⁵

Approved in Europe

The newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system.

¹On a GAAP basis, sales increased 51.7% in Diagnostics; 102.2% in Medical Devices; 3% in Nutrition; 17% in Established Pharmaceuticals. ²Full-year 2018 GAAP EPS guidance of \$1.22 to \$1.32; Midpoint reflects 535% growth on a GAAP basis. ³Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose. For more information about FreeStyle Libre system's indications for use and safety information, please visit: <https://freestylelibre.us/safety-information>. ⁴Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria. ⁵Not available for sale in the United States. ^{*}Comparable operational results are non-GAAP and include the prior year results for St. Jude Medical, and exclude the current year results for Rapid Diagnostics, acquired on Oct. 3, 2017, the impact of exchange and prior and current year results for divested businesses. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 24, 2018.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.